Bothe Melanie K, Meyer Christoph, Mueller Udo, Queudot Jean-Christophe, Roger Virginie, Harleman Johannes, Westphal Martin
Fresenius Kabi Deutschland GmbH, Germany.
Biocrates Life Sciences AG, Austria.
J Toxicol Sci. 2017;42(6):715-721. doi: 10.2131/jts.42.715.
Plasma amino acid level changes occur in mild, moderate and severe stages of liver injury in human patients. In animal models, however, data are mainly restricted to severe liver injury models in rats. Here we present the characterization of a rat model of moderate liver dysfunction secondary to alpha-napthylisothiocyanate (ANIT)-induced cholestasis. Rats treated with 30 mg/kg/day ANIT for 3 weeks exhibited a time-dependent increase in plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin levels and a decrease in albumin concentration. According to a liver dysfunction evaluation based on the human Child-Pugh-Score, animals developed a moderate liver dysfunction in the first two weeks of ANIT treatment, while only a mild dysfunction was observed at the end of week 3 despite ongoing ANIT administration. Univariate analysis of branched-chain amino acid plasma levels indicated that reduced levels of branched chain amino acids were associated with the ANIT treatment. These data may set the stage for further research of amino acid disturbances and requirements in non-severe cholestasis.
在人类患者中,血浆氨基酸水平变化出现在肝损伤的轻度、中度和重度阶段。然而,在动物模型中,数据主要局限于大鼠的重度肝损伤模型。在此,我们展示了一种由α-萘异硫氰酸酯(ANIT)诱导胆汁淤积继发的中度肝功能障碍大鼠模型的特征。用30mg/kg/天的ANIT处理大鼠3周后,血浆丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)和胆红素水平呈时间依赖性升高,白蛋白浓度降低。根据基于人类Child-Pugh评分的肝功能障碍评估,动物在ANIT治疗的前两周出现中度肝功能障碍,而在第3周结束时,尽管持续给予ANIT,仅观察到轻度功能障碍。对支链氨基酸血浆水平的单因素分析表明,支链氨基酸水平降低与ANIT治疗有关。这些数据可能为进一步研究非重度胆汁淤积中氨基酸紊乱和需求奠定基础。